Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- Annals of Laboratory Medicine35(3) · pp.288 · 2015
- 피인용
- Web of Science 22KCI 1
- JCR IF
- JCR 2014 1.417
- ISSN
- 2234-3806
저자
- 박상혁제1저자Pusan National University Hospital
- Hyun Ji LeeKorean Red cross
- 김인숙Pusan National University Yangsan Hospital
- Jeong-Eun KangJinhae Yonsei Hospital
- 이은엽Pusan National University Hospital
- Hyeoung-Joon KimChonnam National University Hwasun Hospital
- Yeo-Kyeoung KimChonnam National University Hwasun Hospital
- Jong-Ho WonSoonchunhyang University Hospital
- Soo-Mee BangSeoul National University Bundang Hospital
- Hawk KimUlsan University Hospital
- 송무곤Pusan National University Hospital
- 정주섭Pusan National University Hospital
- 신호진교신저자Pusan National University
초록
Background: To identify potential molecular prognostic markers in core binding factor (CBF) AML, we analyzed incidences and prognostic impacts of mutations in c-KIT, WT1, CEBPA, CBL, and a number of epigenetic genes in CBF AML. Methods: Seventy one and 21 AML patients with t(8;21) and inv(16) were enrolled in this study, respectively. NPM1, CEBPA, c-KIT, IDH1/2, DNMT3A, EZH2, WT1, and CBL mutations were analyzed by direct sequencing. Patients were categorized with respect to c-KIT and WT1 mutation status, and both clinical features and prognoses were compared. Results: The incidences of FLT3 internal tandem duplication (ITD), NPM1, CEBPA, IDH1/2, DNMT3A, EZH2, and CBL mutations were low (<= 5%) in CBF AML patients. However, c-KIT and WT1 mutations occurred frequently (10.9% and 13.8%, respectively). t(8;21) patients with c-KIT mutations showed significantly shorter overall survival (OS) and disease free survival (DFS) periods than those without mutations (P<0.001, for both); however, although the limited number of t(8;21) patients were analyzed, WT1 mutation status did not affect prognosis significantly. Relapse or death during follow-up occurred more frequently in t(8;21) patients carrying c-KIT mutations than in those without the mutation, although the difference was significant only in a specific patient subgroup with no WT1 mutations (P=0.014). Conclusions: The incidences of mutations in epigenetic genes are very low in CBF AML; however, c-KIT and WT1 mutations occur more frequently than others. The poor prognostic impact of c-KIT mutation in t(8;21) AML patients only applies in a specific patient subgroup without WT1 mutations. The prognostic impact of WT1 mutation in CBF AML is not evident and further investigation is required.
키워드
Acute myeloid leukemiaCore binding factorc-KITEpigenetic modificationIncidencePrognosisWT1RAS GENE-MUTATIONSDNMT3A MUTATIONSNORMAL KARYOTYPENUCLEOPHOSMIN 1FLT3EXPRESSIONNPM1DIAGNOSISAML
식별자
- WoS UID
- 000352754600002
- KCI
- ART001982055



로그인
연구물 목록으로